Date:2/17/2009

made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2007. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

http://www.sanofipasteur.com

http://www.sanofipasteur.us

'/>"/>

SOURCE Sanofi Pasteur Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
2. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
3. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
4. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
5. Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
6. Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
7. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
8. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
9. Presbyterian Hospital Dallas Starts Advanced Breast-Cancer Risk-Assessment Program
10. U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
11. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine